Dietary Non-protein Amino Acid AZE as an Environmental Trigger Activating Latent Genetic Susceptibility in C9orf72-ALS Pathogenesis
簡介:
- 作者: Chongjiu Chen, Zhanyun Lv, Guangyu Cui, Hui Gong, Jianfeng Hua, Tao Luo, Hongyun Bi, Xinrui Zhang, Qinqin Cui, Hongying Zhu, Xing Guo, Nengyin Sheng, Chengyong Shen, Dongsheng Fan, Ke Zhang, Huaqing Liu, Ge Bai
- 雜志: BioRxiv
- Doi: https://www.doi.org/10.64898/2026.01.12.697838
- 出版日期: 2026/1/13
摘要
In human disease, clinical manifestations are not always tightly correlated with genetic etiology. While the GGGGCC (G4C2) hexanucleotide repeat expansion in the C9orf72 gene is the most prevalent genetic cause of ALS, a subset of mutation carriers stays asymptomatic. The molecular mechanisms underlying this incomplete penetrance remain elusive. Here, we identify L-azetidine-2-carboxylic acid (AZE), a dietary non-protein amino acid, as a critical environmental risk factor capable of unmasking latent genetic susceptibility in C9orf72-ALS pathogenesis. Specifically, AZE disrupts the proteasome-mediated clearance of toxic poly-GA dipeptide repeats derived from G4C2 repeats, triggering pronounced neuroinflammation and motor defects in a C9orf72-ALS mouse model that otherwise exhibits minimal phenotypes. Notably, AZE is widely present in the food chain (particularly in sugar beet) and consistently detectable in the postmortem human brains. A significant positive correlation was observed between sugar beet consumption and the incidence of sporadic C9-ALS cases in European nations. Critically, dietary intake of sugar beet juice is sufficient to activate subclinical genetic susceptibility in C9orf72-ALS mice. These findings reveal a direct diet-gene interplay in governing C9orf72-ALS penetrance, and propose dietary restriction of AZE-rich foods as a tangible strategy for genetically susceptible individuals to potentially delay or mitigate this currently incurable disorder.
關于派真
作為一家專注于AAV 技術十余年,深耕基因治療領域的CRO&CDMO,派真生物可提供從載體設計、構建到 AAV、慢病毒和 mRNA 服務的一站式解決方案。憑借深厚的技術實力、卓越的運營管理和高標準的服務交付,我們為全球客戶提供一站式CMC解決方案,包括從早期概念驗證、成藥性評估到IIT、IND及BLA的各個階段。
?
憑借我們獨立知識產權的π-alphaTM 293 細胞AAV高產技術平臺,我們能將AAV產量提高多至10倍,每批次產量可達1×101?vg,以滿足多樣化的商業化和臨床項目需求。此外,我們定制化的mRNA和脂質納米顆粒(LNP)產品及服務覆蓋藥物和疫苗開發的各個階段,從研發到符合GMP的生產,提供端到端的一站式解決方案。